{"pmid":32385549,"title":"COVID-19, Angiotensin Receptor Blockers, and the Brain.","text":["COVID-19, Angiotensin Receptor Blockers, and the Brain.","Cell Mol Neurobiol","Saavedra, Juan M","32385549"],"journal":"Cell Mol Neurobiol","authors":["Saavedra, Juan M"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385549","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s10571-020-00861-y","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340102005063680,"score":9.490897,"similar":[{"pmid":32304747,"pmcid":"PMC7158830","title":"Angiotensin receptor blockers and COVID-19.","text":["Angiotensin receptor blockers and COVID-19.","Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients.","Pharmacol Res","Saavedra, Juan M","32304747"],"abstract":["Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients."],"journal":"Pharmacol Res","authors":["Saavedra, Juan M"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304747","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.phrs.2020.104832","keywords":["ace2","angiotensin receptor blockers","covid-19","coronavirus","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491087486979,"score":63.849304},{"pmid":32473311,"title":"Angiotensin receptor blockers for the treatment of covid-19 and its comorbidities.","text":["Angiotensin receptor blockers for the treatment of covid-19 and its comorbidities.","Pharmacol Res","Saavedra, Juan M","32473311"],"journal":"Pharmacol Res","authors":["Saavedra, Juan M"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473311","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.phrs.2020.104958","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193298370561,"score":58.644672},{"pmid":32371811,"title":"Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.","text":["Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.","J Hypertens","Verdecchia, Paolo","Angeli, Fabio","Reboldi, Gianpaolo","32371811"],"journal":"J Hypertens","authors":["Verdecchia, Paolo","Angeli, Fabio","Reboldi, Gianpaolo"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371811","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1097/HJH.0000000000002469","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496475070464,"score":58.28838},{"pmid":32208485,"title":"COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?","text":["COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?","JAMA","Patel, Ankit B","Verma, Ashish","32208485"],"journal":"JAMA","authors":["Patel, Ankit B","Verma, Ashish"],"date":"2020-03-26T11:00:00Z","year":2020,"_id":"32208485","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jama.2020.4812","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490196197376,"score":56.517487},{"pmid":32422077,"title":"COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.","text":["COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.","Ann Intern Med","Kussmaul, William G 3rd","32422077"],"journal":"Ann Intern Med","authors":["Kussmaul, William G 3rd"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422077","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.7326/M20-3047","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284416249856,"score":56.517487}]}